1. Home
  2. BDTX vs TGL Comparison

BDTX vs TGL Comparison

Compare BDTX & TGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$2.65

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

TGL

Treasure Global Inc.

HOLD

Current Price

$4.02

Market Cap

7.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDTX
TGL
Founded
2014
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
171.9M
7.2M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
BDTX
TGL
Price
$2.65
$4.02
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$9.67
N/A
AVG Volume (30 Days)
1.4M
14.6K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
130.71
N/A
EPS
N/A
N/A
Revenue
N/A
$2,330,557.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.93
$0.26
52 Week High
$4.94
$58.00

Technical Indicators

Market Signals
Indicator
BDTX
TGL
Relative Strength Index (RSI) 45.91 48.01
Support Level $2.28 $4.03
Resistance Level $2.67 $4.30
Average True Range (ATR) 0.33 0.31
MACD 0.01 -0.04
Stochastic Oscillator 13.96 29.77

Price Performance

Historical Comparison
BDTX
TGL

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

About TGL Treasure Global Inc.

Treasure Global Inc has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: payment processing and e-commerce operation in its ZCITY platform, and customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.

Share on Social Networks: